Bet-CA significantly suppressed VEGF secretion by 4T1 cells after 24 h (Fig. 6B, Supplementary Figs S7 and S8) and encouraged by the in vitro results, we addressed this issue in vivo and testified whether the therapeutic physiological concentration of Bet-CA could similarly reverse VEGF production in breast tumor bearing mice. The gene discussed is VEGFA; the disease is breast neoplasm.